- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this phase II study in castration-resistant metastatic prostate cancer patients who have had orciectomy or are receiving an LHRH analogue is to demonstrate a prolonged progression-fee survival (PFS) in the group treated with sorafenib and bicalutamide in comparison to those treated with placebo and bicalutamide.
Critère d'inclusion
- metastatic prostate cancer